Diatech Pharmacogenetics is pleased to announce the launch of the kit Myriapod Colon status (code SQ010).
Using MALDI-TOF Mass Spectrometry technology associated with the Single Base Extension, Myriapod Colon status allows the parallel analysis of 153 mutations in the 4 major oncogenes involved in the pathogenesis of colorectal cancer (KRAS, BRAF, PIK3CA, NRAS). To many of them, the last two decades, has been a recognized prognostic and predictive value for specific targeted therapies. For a complete list of the mutations detected by the kit, see the table in the Annex.
The panel consists of 8 multiplex reactions, for each of which are needed 5-50 ng of DNA, extracted from fresh tissue, frozen or paraffin, or from cells.
The kit contains all reagents and consumables necessary for the execution of 120 tests, divided into 10 independent analytical sessions, each for 10 clinical samples and 2 controls the reaction, respectively positive (wild-type human genomic DNA for all variants investigated) and negative, which are also included into the product.
The system allows to genotype automatically and completely reproducible, samples with an accuracy ? 99.7% and a sensitivity of up to 2.5% of mutated allele.
For a complete list of the mutations detected by the kit, you can write to: email@example.com